In addition, tolerance represents a clinical limitation; thus, LABAs are best used in combination with PDE4 inhibitors, or corticosteroids (restricted to the eosinophilic COPD phenotype). This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.